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http://www.biomedcentral.com/1471-2253/14/103RESEARCH ARTICLE Open AccessThe combination of MELD score and ICG liver
testing predicts length of stay in the ICU and
hospital mortality in liver transplant recipients
Stephanie Klinzing1, Giovanna Brandi1, Paul A Stehberger1, Dimitri A Raptis2 and Markus Béchir1*Abstract
Background: Early prediction of outcome would be useful for an optimal intensive care management of liver
transplant recipients. Indocyanine green clearance can be measured non-invasively by pulse spectrophometry and
is closely related to liver function.
Methods: This study was undertaken to assess the predictive value of a combination of the model of end stage
liver disease (MELD) score and early indocyanine plasma disappearance rates (ICG-PDR) for length of stay in the
intensive care unit (ICU), length of stay in the hospital and hospital mortality in liver transplant recipients.
Results: Fifty consecutive liver transplant recipients were included in this post Hoc single-center study. ICG-PDR
was determined within 6 hours after ICU admission. Endpoints were length of stay in the ICU, length of hospital
stay and hospital mortality. The combination of a high MELD score (MELD >25) and a low ICG-PDR clearance
(ICG-PDR < 20%/minute) predicts a significant longer stay in the ICU (p = 0.004), a significant longer stay in the
hospital (p < 0.001) and a hospital mortality of 40% vs. 0% (p = 0.003).
Conclusion: The combination of MELD scores and a singular ICG-PDR measurement in the early postoperative
phase is an accurate predictor for outcome in liver transplant recipients. This easy-to-assess tool might be valuable
for an optimal intensive care management of those patients.
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In 2002, the United Network for Organ Sharing introduced
a new allocation policy for cadaveric liver transplants based
on the end-stage liver disease (MELD) scoring system [1].
However, while the MELD score is an accurate predictor
of waiting list mortality [2,3], recipient-derived methods
including MELD [4-7] and, for example, the Child-Pugh
score [5,8] poorly predict mortality in liver transplant re-
cipients. Similarly graft derived methods like the donor
risk index, also has poor predictive value [9]. The 2008
Survival Outcomes Following Liver Transplant (SOFT)
Score [10], on the other hand, incorporates 18 recipient-
and donor- derived factors as well as operative factors* Correspondence: markus.bechir@paraplegie.ch
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reproduction in any medium, provided the orand, as a result, accurately predicts short-term recipient
survival following liver transplantation.
Due to the improvement in surgical techniques and a
reduction in allograft rejection, the 1-year patient and
graft survival is 90% [4,11,12], with the highest mortality
rate during the early postoperative period in the critical
care unit [13,14]. Major complications occurring in the
early postoperative phase are mainly due to graft non-
function, acute rejection, sepsis, neurological complica-
tions and haemorrhagic shock.
Only limited date on the critical care management of
and complications in liver transplant recipients are avail-
able [15-18]. Therefore, an easy-to-assess test with good
accuracy would be valuable for outcome prediction and
risk stratification in the postoperative phase of liver
transplant patients.
High MELD scores reflect the severity of liver disease be-
fore transplantation and are associated with postoperativel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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factors which predict postoperative outcome of liver trans-
plant recipients. The assessment of post-transplant liver
function traditionally is based on several nonspecific liver
function tests that are difficult to interpret and need serial
observation [20]. Indocyanine green (ICG) is closely corre-
lated with hepatic function due to its hepatic metaboliza-
tion. It has proven to predict outcome in critically ill [21]
and septic patients [22], but its relevance in liver trans-
plantation is elusive [23,24]. Classically ICG measurements
were performed either by spectrophotometry [25] or with
a fiber-optic aortic catheter placed through the femoral ar-
tery [26]. Both methods correlate well with graft function,
but are time consuming, expensive or invasive. On the
other hand, the method of non-invasive ICG measurement
based on pulse dye measurement using a finger-clip corre-
lates well with the classical measurements [27], but it is
non-invasive and easy to use.
Therefore we evaluated the predictive power of pre-
operative MELD, postoperative ICG measurement and a
combination of these values regarding length of stay in
the ICU, length of stay in the hospital and mortality by
performing single and combined ROC analysis.
Methods
From September 2007 to June 2009, 50 consecutive pa-
tients who underwent transplantation at our center and
received an ICG test within six hours after admission to
the ICU were included in this Post Hoc analysis. Follow-
ing approval by the local ethic committee (KEK Kantonale
Ethik Kommission [Cantonal Ethical Committee] 4,
Canton Zurich), all patients gave written informed con-
sent before transplantation for postoperative data analysis.
ICG liver test
The ICG liver testing was performed noninvasively by
pulse spectrophotometry (LiMON®, Pulsion Medical
Systems AG, Munich, Germany). After intravenous in-
jection ICG-bolus (0.25 mg/kg; ICG Pulsion Medical
Systems AG, Munich, Germany), plasma ICG concen-
trations were determined by pulse spectrophotometry
with a finger-clip sensor that detects two near-infrared
wavelengths.
The plasma disappearance rate of ICG (ICG-PDR) was
calculated automatically by the time course of the blood
ICG concentration (normal value: ICG-PDR ≥ 16%/minute).
After ICU admission, volume was assessed with passive
leg raise test and focused transthoracic echocardiography
and corrected if necessary. ICG-PDR measurements were
performed within 6 hours from admission to the ICU.
Operative technique
All livers were transplanted without a veno-venous by-
pass, as described by McCormack and colleagues [28].Baseline data
Gender, age and body mass index were collected for re-
cipients and donors. For recipients, uncorrected MELD
scores, SAPS II as well the incidence of renal replace-
ment therapy (RRT) and hepato-renal-syndrome (HRS)
before transplantation were recorded. The values of cre-
atinine, haematocrit, platelets, INR and bilirubin immedi-
ately prior to transplantation were gathered. Creatinine
values for patients on RRT were excluded. HRS was
defined according to the definitions by Arroy [29] and
Salerno [30].
The incidence of cadaveric or living donors as well as
extended donor criteria was registered. Extended donor
criteria (marginal grafts) were defined as age of 65 years
or older, cold ischemia time of 720 minutes or longer, or
biopsy-proven steatosis (micro- or macrovascular in ≥60%
of hepatocytes or ≥30% macrovascular steatosis) [31].
ICU data
The ICG-PDR was measured within the first 6 hours
after admission, the factor V 24 hours after transplant-
ation, and the peak values for bilirubin during the first
postoperative week were recorded.
Data concerning length of ICU and hospital stay were
collected and hospital mortality was recorded.
Statistical analysis
Continuous variables were compared with the Mann-
Whitney U, or Kruskal-Wallis tests, where appropriate.
Differences among proportions were compared using
the Fischer’s Exact or the Pearson χ2 tests, where appro-
priate. All p values were two-sided and considered statisti-
cally significant if p ≤0.05. Sensitivity, specificity, accuracy,
diagnostic odds ratio (OR), and the receiver operator
characteristic (ROC) curve were also calculated [32-36].
According to the results, a cut off of 4 days for length of
stay in the ICU and 37 days for length of stay in the
hospital was determined. Thereafter a logistic regres-
sion model including gender, age, BMI and the combined
MELD/ICG score was performed. Statistical analysis was
performed using SPSS Statistics version 20 (SPSS: An IBM
Company, Chicago IL, 2012).
Results
Demographic data and baseline characteristics are shown
in Table 1. The postoperative ICU results are presented in
Table 2.
Twenty-seven patients stayed in the ICU for more
than four days and thirteen patients had a hospital stay
of more than thirty-seven days (Table 3). Patients with
an ICU stay longer than four days were characterized by
a significantly higher MELD score (p = 0.007), signifi-
cantly decreased ICG-PDR (p = 0.001), significantly ele-
vated peak bilirubin within the first postoperative week
Table 1 Demographic data of the recipients and donors
(n = 50)
Recipient Donor
Male (%) 37 (74%) 36 (72%)
Female (%) 13 (26%) 14 (28%)
Age (yrs) 51.3 ± 11.1 (16 - 67) 53.2 ± 17.2 (19 - 86)
BMI (kg/m2) 25.7 ± 4.73 (16.6 - 42.9) 24.3 ± 3.3 (16.0- 31.0)
MELD 21 ± 10.4 (6 - 40)
RRT before TPL (%) 8 (16%)
HRS before TPL (%) 17 (34%)
SAPS II 30 ± 19 (0 - 91)
Creatinine (μmol/l) 121 ± 117 (40 - 814)
Hematocrit (%) 31.4 ± 7.6 (18.8 - 49.6)
Platelets (103/μl) 106 ± 65 (33 - 324)
INR 1.5 ± 0.6 (0.9 - 4.3)
Bilirubin (μmol/l) 148 ± 198 (5 - 875)
Etiology of liver disease
HCV (%) 17 (34%)
HBV (%) 3 (6%)
HCC (%) 10 (20%)
Alcoholic liver cirrhosis (%) 6 (12%)
Cholangiocarcinoma (%) 2 (4%)
Others1 (%) 12 (24%)
Cadaveric Donor (%) 44 (88%)




Data expressed as mean± standard deviation (range). Abbreviations: BMI, body
mass index; RRT, renal replacement therapy; TPL, transplantation; HRS, hepato-renal
syndrome; SAPS, simplified acute physiology score; INR, international normalized
ratio; HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
Footnote: 1) encompasses primary biliary cirrhosis, primary sclerosing cholangitis,
autoimmune hepatitis liver cirrhosis, Morbus Wilson, alpha-1-antitrypsin-defiency,
acute liver failure, cryptogenic liver cirrhosis, Morbus Osler, polycyclic liver disease,
recurrent intrahepatic cholestasis, vanishing bile duct
syndrome, haemangioendothelioma.
Table 2 Postoperative ICU data (n = 50)
ICG-PDR (%/min)1 19.5 ± 7.7 (4.2 - 34)
Bilirubin (μmol/l)2 133 ± 115 (17 - 568)
Factor V (%)3 57 ± 29 (4 - 114)
ICU stay (days) 11.6 ± 21.9 (1 - 93)
Hospital stay (days) 31.4 ± 28.0 (8 - 128)
Hospital Mortality (%) 4 (8%)
Data expressed as mean ± standard deviation (range). Abbreviations: ICG-PDR,
indocyanine green plasma disappearance rate. Footnotes: 1) determined within
6 hours after ICU admission, 2) peak values within 7 days, 3) after 24 hours.
Klinzing et al. BMC Anesthesiology 2014, 14:103 Page 3 of 7
http://www.biomedcentral.com/1471-2253/14/103(p = 0.03) and significantly decreased factor V within the
first 24 hours after operation (p = 0.03). Patients with a
prolonged hospital stay over 37 days were characterized
by significantly higher MELD score (p < 0.001) and sig-
nificantly elevated peak bilirubin within the first postop-
erative week (p = 0.008).
A ROC analysis was performed, which is presented in
Table 4 and Figure 1. According to the determined cut
off value, a MELD >25 was significant for prolonged
ICU stay over four days (OR 4.12, 95% confidence interval
(95% CI) 1.2 - 13.8, p = 0.024) and a prolonged hospital
stay over 37 days (OR 13.0, 95% CI 2.5 - 68.6, p = 0.001).
ICG-PDR < 20%/min was significant for prolonged ICU
stay (OR 3.54, 95% CI 1.1-11.8, p = 0.047) and prolonged
hospital stay (OR 4.67, 95% CI 1.20-18.34, p = 0.027)
respectively. Peak bilirubin >100 μmol/l within the firstpostoperative week was significant for a prolonged
hospital stay (OR = 0.063, 95% CI 0.007-0.54, p = 0.01)
but not for prolonged ICU stay (OR = 0.39, 95% CI
0.12-1.21, p = 0.10). Factor V measurement 24 hours
postoperatively failed to achieve significance for both
length of stay in the ICU (OR = 0.35, 95% CI 0.11-1.13,
p = 0.09) and length of hospital stay (OR = 2.13; 95% CI
0.56-8.16, p = 0.34). Four patients (8%) died during
hospitalization, characterized by significantly higher MELD
scores (p = 0.032) and significantly decreased ICG-PDR
(p = 0.026) compared to survivors. Peak bilirubin (p = 0.12)
and factor V (p = 0.31) were not significantly different
between survivors and non-survivors.
Based on these findings, a combination of MELD and
ICG-PDR was tested. A positive MELD/ICG-PDR combin-
ation was defined as a high MELD score (MELD score > 25)
and a decreased ICG-PDR (ICG-PDR< 20%/min), while all
other possible combinations were defined to be a negative
combination (Table 5).
A positive MELD and ICG-PDR combination pre-
dicted a twice as long ICU length of stay of median
9 days (p = 0.004) and a twice as long hospital stay of
median 42 days (p < 0.001) compared to all other pos-
sible combinations. Hospital Mortality in case of positive
combination was 40%, while it was 0% in case of nega-
tive combination (p = 0.003).
A multivariate analysis of ICU length stay selected the
MELD/ICG combination as the most prediciting factor,
while OR could not be calculated because all cases were
discriminated. BMI was significant in this analysis with
p = 0.007 (OR 9.61, 95% CI 1.88-26.5). Gender and age
were not significant in this analysis (p = 0.16 and p = 0.11
respectively). Concerning Hospital length of stay, the
MELD/ICG combination was significant with p = 0.006
(OR 64.17, 95% CI 3.3-1253) and age was significant with
p = 0.045 (OR 22.63, 95% CI 1.08-415.2). Gender and BMI
were not significant in this analysis (p = 0.61 and p = 0.60
respectively).
Discussion
The major new findings of this study - undertaken to de-
termine whether an easy-to-use combination of a singu-
lar ICG-PDR measurement early after transplantation
Table 3 ICU and hospital stay grouped data
ICU stay ≤4 days ICU stay >4 days p Hospital stay ≤37 days Hospital stay >37 days p
(n = 23) (n = 27) (n = 37) (n = 13)
Age (yrs) 50 (45-58) 55 (48 - 61) 0.11 50 (45 - 58) 58 (51 - 63) 0.033
BMI (kg/m2) 23.8 (21.1-26.6) 26.4 (25.0 - 28.6) 0.04 25.4 (22.7 - 28.5) 25.5 (24.2 - 26.2) 0.72
MELD 14 (86-27) 26 (18 - 32) 0.007 18 (10 - 26) 28 (26 - 34) <0.001
ICG-PDR (%/min)1 23.4 (18.7-26.7) 16.6 (8.8 - 22.8) 0.001 22.8 (15.5 - 25.3) 17.6 (10.1 - 20.8) 0.08
Bilirubin (μmol/l)2 94 (22-149) 133 (61 - 214) 0.03 88 (37 - 156) 162 (116 - 214) 0.008
Factor V (%)3 71 (41-92) 45 (27 - 66) 0.03 53 (30 - 73) 66 (49 - 83) 0.35
Data expressed as median (25th - 75th Percentile). Footnotes: 1) determined within 6 hours after ICU admission, 2) peak values within 7 days, 3) after 24 hours.
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hospital stay and hospital mortality - are that the posi-
tive combination of a high MELD score and a low ICG-
PDR predicts a significantly longer stay in the ICU
(9 days vs. 4 days) and a significantly longer hospital stay
(42 days vs. 22 days) as well as a significantly higher hos-
pital mortality (40% vs. 0%) compared to liver transplant
recipients with a negative score.
The main limitations of our study are its small sample
size and the post-hoc design, but nevertheless the results
are promising and should be validated in another pro-
spective collected dataset of liver transplant patients.
Our easy-to-use assessment combines the MELD score,
for which it has been proven that high scores are associ-
ated with a prolonged postoperative course [4,19] with an
early postoperative ICG-PDR measurement of global liver
function.
Low ICG-PDR values in the early postoperative phase of
liver transplant recipients predict complications duringTable 4 Receiver operating characteristic analysis of MELD, IC




ICG-PDR (%/min)1 20 0.77
Bilirubin (μmol/l)2 110 0.68
Factor V (%)3 40 0.75
Hospital stay
MELD 23 0.81
ICG-PDR (%/min)1 20 0.67
Bilirubin (μmol/l)2 110 0.75
Factor V (%)3 50 0.52
Hospital mortality
MELD 25 0.85
ICG-PDR (%/min)1 20 0.79
Bilirubin (μmol/l)2 110 0.68
Factor V (%)3 40 0.72
Abbreviations: AUC, area under the curve. Footnotes: 1) determined within 6 hours athe early postoperative period [23,24] while normal values
have been shown to predict an uncomplicated postopera-
tive course [37]. Outcome prediction by ICG-PDR values
has yielded conflicting results [24,37,38].
Measurement of ICG-PDR is an accurate test for evaluat-
ing liver function, but, as shown by Levesque’s results [23],
its limitation is the lack to identify the underlying cause of a
dysfunction. ICG-PDR is a test for global hepato-splanchnic
blood flow and biliary excretion. Therefore, changes in ICG-
PDR may be due to local disturbances in hepatic blood flow
or systemic disturbances. It has been proved that absence of
flow in the hepatic artery and primary graft dysfunction or
non-function leads to diminished ICG-PDR [39,40]. More-
over, it has been shown that ICG-PDR in patients with sep-
tic shock is reduced due to hepatocellular dysfunction [22].
For sepsis, it has been shown that recovery and survival is
related to the course of repeated ICG-PDR measurements,
where continuously low ICG-PDR over time is associated
high mortality [22,23].G-PDR, bilirubin and factor V to predict the length of stay













fter ICU admission, 2) peak values within 7 days, 3) after 24 hours.
Figure 1 ROC curve analysis of parameters with different clinical outcomes. (A) Area under the curve (AUC) for MELD and ICU stay (≤4 vs. >4),
(B) ICG and ICU stay, (C) MELD and hospital stay (≤37 vs. >37), (D) ICG and hospital stay, (E) MELD and hospital mortality, and (F) ICG and
hospital mortality.
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Due to early assessment in the postoperative course, the
combination of MELD scores and early postoperative
ICG-PDR measurement might be valuable to identify
risk patients in term of prolonged postoperative course
and increased mortality and to prompt appropriateintensive care actions without time delay. This in-
cludes reassurement of hepatic blood flow by Doppler
ultrasound, angiographic computed tomography or arteri-
ography as well as calculated volume management and
early goal-directed therapy in case of sepsis [41]. The
negative combination of MELD scores and ICG-PDR
Table 5 MELD / ICG-PDR combination for prediction of







ICU stay, median (IQR) 9 (5-43) 4 (3-6) 0.004
Hospital stay, median (IQR) 42 (21-74) 22 (15-28) < 0.001
Hospital mortality, n (%) 4 (40%) 0 (0% ) 0.003
Positive combination: MELD >25 and ICG-PDR <20%/min. Negative combination:
all other combinations. Abbreviations: IQR, interquartile range, SEM, standard error
of mean.
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course and low mortality. This negative predictive value is
in agreement with the ICG-PDR data reported by
Schneider [37] and may be useful as a criterion for
transferring patients from the ICU to a peripheral
ward and allows optimal utilisation of the ICU resources.
While the combination of the MELD score and a sin-
gular ICG-PDR measurement in the early postoperative
phase and BMI were identified as predictors of ICU
length of stay, the combination of MELD score and
ICG-PDR and age were identified as predictors for hos-
pital length of stay. Therefore, the MELD and ICG-PDR
combination seems to be the best predictor and risk
stratificator in liver transplanted recipients admitted to
the ICU in terms of ICU length of stay, hospital length
of stay and hospital mortality.
Conclusion
In conclusion, the combination of the preoperative MELD
score and a singular ICG-PDR measurement in the early
postoperative phase (within six hours) is an interesting
and easy to assess tool that should be addressed in a larger
cohort of patients to evaluate its usefulness in terms of
risk stratification and outcome prediction.
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